Investor Presentaiton

Oncology Hematology Cell Therapy Immunology Cardiovascular obexelimab (CD19 x FcyRIIB bifunctional mAb) Indication Phase/Study # of Patients Obexelimab SC Placebo SC Design IgG4-Related Disease (ex-US study) Phase III INDIGO Non-BMS Sponsored* N = 200 Endpoints Primary: Time to first IgG4-RD flare that requires initiation of rescue therapy in the opinion of the investigator and the Adjudication Committee (AC) from randomization to Week 52 • Recruiting Status Expected data readout 2025 CT Identifier NCT05662241 ll Bristol Myers Squibb Q3 2023 Results *Trial conducted by Zenas BioPharma Not for Product Promotional Use 53

View entire presentation